Operator
Greetings, and welcome to the Global Blood Therapeutics conference call. [Operator instructions] I would now like to turn the call over to Steven Immergut. Please, go ahead.
Steven Immergut
Senior Vice President, Head of Corporate Communications and Investor Relations
Thank you, and welcome to GBT s conference call to discuss the Company s financial results for the first quarter of 2021 and to provide a business update. I m Steven Immergut, head of communications and investor relations. Joining me on the call are Dr. Ted Love, our president and CEO, who will provide an update on our progress in the first quarter; Jeff Farrow, our chief financial officer, who will review our financial results; David Johnson, or DJ, our chief commercial officer, will give an update on the Oxbryta launch. Ted will then introduce Dr.
Markets
In a report released today, Danielle Brill from Raymond James maintained a Buy rating on PTC Therapeutics (PTCT – Research Report). The company’s shares closed last Wednesday at $45.96, close to its 52-week low of $43.65.
According to TipRanks.com, Brill is a 4-star analyst with an average return of 14.4% and a 50.3% success rate. Brill covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, ACADIA Pharmaceuticals, and Sarepta Therapeutics.
Currently, the analyst consensus on PTC Therapeutics is a Moderate Buy with an average price target of $66.75, which is a 44.6% upside from current levels. In a report issued on April 15, William Blair also maintained a Buy rating on the stock.
Solid Bio, eyeing comeback, points to totality of new Duchenne gene therapy results biopharmadive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharmadive.com Daily Mail and Mail on Sunday newspapers.
Needham upgraded shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) from Hold to Buy, with a price target of $155. The price target, according to the firm, is based on 25 times its estimated earnings per share for 2022, discounted 20 percent annually.
Analysts Alan Carr and Danielle. Read More. Don t Miss Any Updates! News Directly in Your Inbox Subscribe to:
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) - Why 2 Acadia Pharma Analysts Are Bracing For FDA Rejection Of Nuplazid In Dementia benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.